A Nationwide Survey of Adoption and Perception of Pharmacogenomic Testing by U.S. Cardiologists

Stanek, Eric J.; Sanders, Christopher; Agatep, Barnabie C; Johansen, Katherine A.; Aubert, Ronald E.; Khalid, Mona Aeysha; Patel, Aanal; Frueh, Felix W.; Epstein, Robert S.

doi:10.1016/s0735-1097(11)61283-7

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, psychiatrists (with the second largest number of approved FDA biomarkers) have not fully embraced PGx testing in clinical practice. 16,17 In addition, consistent with Parker and Satkoske, 18 the FDA acknowledges that one key limitation of these labels is that the efficacy of PGx has not been established with minority populations. 12 Moreover, due to the history of the United States government conducting unethical medical experimentation under the guise of clinical trials and treatment with these populations, 18 such efficacy testing is likely to be a sensitive issue.…”

Section: Considerations For Pgx Clinical Usementioning

confidence: 89%

See 1 more Smart Citation

Landmarks of pharmacogenomics and some considerations for clinical practice

Ampong

2019

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Since the completion of the Human Genome Project 28 years ago, myriad genomics applications have risen in areas such as agriculture, livestock, infectious agents, forensics, bioenergy, ancestry, health, disease, and medicine. This was driven partly by the US government’s ability to use a unique program to facilitate genome sequencing to the point where the cost of sequencing a whole human genome is not prohibitive. However, application of this knowledge of the double helix twisted DNA at the bedside in psychiatric clinical practice has little to report, despite US Food and Drug Administration (FDA) approval of nearly 40 psychotropic drugs, as well as specific guidelines for their application. Patients with treatment-resistant mental illness, history of unresponsiveness to psychotropic medications, and history or family history of serious adverse effects to psychotropic drugs may qualify for pharmacogenomics (PGx) testing with insurance reimbursement, or a low, out-of-pocket, payment of not greater than US $300. Psychiatric mental health nurse practitioners and providers who utilize PGx will not only improve patient care outcomes, but also contribute to the acceleration of the potential diagnostic and preventive capabilities of PGx testing.

show abstract

Section: Considerations For Pgx Clinical Usementioning

confidence: 89%

“…However, psychiatrists (with the second largest number of approved FDA biomarkers) have not fully embraced PGx testing in clinical practice. 16 , 17 …”

Section: Discussionmentioning

confidence: 99%

Landmarks of pharmacogenomics and some considerations for clinical practice

Ampong

2019

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

show abstract

A Nationwide Survey of Adoption and Perception of Pharmacogenomic Testing by U.S. Cardiologists

Cited by 1 publication

References 0 publications

Landmarks of pharmacogenomics and some considerations for clinical practice

Landmarks of pharmacogenomics and some considerations for clinical practice

Contact Info

Product

Resources

About